Diagnosis and management of Chronic Hepatitis C

Canadian Journal of Gastroenterology

Volumn 14, Issue SUPPL. B, 2000, Pages

  Pár, Alajos ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Chronic hepatitis C; Diagnosis; Hepatitis C; Interferon; Prevention; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIVIRUS AGENT; RIBAVIRIN;

BLOOD; DRUG COMBINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HUMAN; MALE; MASS SCREENING; POLYMERASE CHAIN REACTION; REVIEW;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MASS SCREENING; POLYMERASE CHAIN REACTION; RIBAVIRIN;

EID: 0034221123     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2000/707182     Document Type: Article

References (33)

1. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997;26(Suppl 1):62-5.
2. World Health Organization. Hepatitis C. Wkly Epidemiol Rec 1997;72:65-9.
3. Hoofnagle JH. Therapy of viral hepatitis. Digestion 1998;59:563-78.
4. Alter MJ, Mast EE, Moyer LA, Margolis HS. Hepatitis C. Infect Dis Clin North Am 1998;12:13-26.
5. Simmonds P. Variability of hepatitis C virus. Hepatology 1995;21:570-83.
6. Pár A, Gervain J, Gógl Á. Hepatitis C virus infection: pathogenesis, diagnosis and treatment. Scand J Gastroenterol 1998;33(Suppl 228):107-14.
7. Hoofnagle JH. Hepatitis C. The clinical spectrum. Hepatology 1997;26:15S-20S.
8. Gordon SC, Schiff ER. Hepatitis C virus. Curr Pract Med 1999;2:935-42.
9. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A non-B hepatitis with recombinant human alpha interferon. N Engl J Med 1986;315:1575-8.
10. Poynard T, Bedossa P, Chevallier M and the Multicentre Study Group. A comparison of three interferon alpha-2b regimens for the long term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995;332:1457-62.
11. Chemello L, Bonetti P, Cavaletta L. Randomized trial comparing three different regimes of alpha-2a interferon in chronic hepatitis C. Hepatology 1995;22:700-6.
12. Niederau C, Heintges T, Haussinger D. Treatment of chronic hepatitis C with alpha-interferon: an analysis of the literature. Hepatogastroenterology 1996;43:1544-56.
13. Lau DTY, Kleiner DE, Chang MG, Park Y, Schmid P, Hoofnagle JH. 10-year follow-up after interferon alpha therapy for chronic hepatitis C. Hepatology 1998;28:1121-7.
14. Iino S, Hino K, Kuroki T, Suzuki H, Yamamoto S. Treatment of chronic hepatitis C with high-dose alpha-2b. Dig Dis Sci 1993;38:612-8.
15. Hu Z-X, Hoffman J, Patel I, Joubert P. Single-dose safety, tolerability and pharmacokinetic/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated-interferon (PEG-IFN) and interferon α-2a (IFN α-2a) to healthy Subjects. Hepatology 1998;28:702A.
16. Lindsay KL. Different types of interferon. EASL International Consensus Conference on Hepatitis C. Paris, February 26-27, 1999.
17. Reichard O, Norkrans G, Fryden A. Interferon alpha and ribavirin vs interferon alone as therapy for chronic hepatitis C. Hepatology 1996:24:356A.
18. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
19. Reichard O, Norkrans G, Fryden A, Braconier J-H, Sonnerborg A, Weiland A. Randomised, double blind, placebo controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet 1998;351:83-7.
20. Davis GL, Esteban-Mur R, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:1493-9.
21. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alphas2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-32.
22. Love RA, Parge HE, Wichersham JA. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsine-like fold and a structural zinc binding site. Cell 1996;87:331-42.
23. EASL International Consensus Conference on Hepatitis C. Paris, February 26-27,1999. Consensus Statement. J Hepatology 1999;30:956-61.
24. Kakumu S, Aiyama T, Okumara A, Iwata K, Ishikawa T, Yoshioka K. Earlier loss of hepatitis C virus RNA in interferon therapy can predict a long term response in chronic hepatitis C. J Gastroenterol Hepatol 1997;12:468-72.
25. Lee WM, Redd KR, Tong MJ, et al, and Consensus Interferon Study Group. Early hepatitis C virus RNA responses predict interferon treatment outcomes in chronic hepatitis C. Hepatology 1998;28:1411-5.
26. Craxi A, Camma C, Giunta M. Definition of response. EASL International Consensus Conference on Hepatitis C. Paris, February 26-27, 1999.
27. Alberti A. Long-term effects of extended duration of interferon treatment for chronic hepatitis C. International Symposium on Hepatitis C at AASLD Annual Meeting, Chicago, November 8-12, 1996.
28. Davis GL, Lau JYN. Factors predictive of beneficial response to therapy of hepatitis C. Hepatology 1997;26:112S-27S.
29. Pár A, Paál M, Horányi M, et al. Role of viral and host factors in the pathogenesis of hepatitis C virus infection and in the response to interferon treatment. Period Biol 19998;100:515-9.
30. Samuel D. Viral recurrence and liver transplantation. EASL International Consensus Conference on Hepatitis C. Paris, February 26-27, 1999.
31. Farci P, Shimodo A, Wong D, et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci USA 1996;93:15394-9.
32. Purcell R. The hepatitis C virus: Overview. Hepatology 1997;26(Suppl 1):1-14.
33. Gordon, SC, Bayati N, Silverman AL. Clinical outcome of hepatitis C as a function of mode of transmission. Hepatology 1998;28:562-7.